Brokerages Set Biogen Inc. (NASDAQ:BIIB) PT at $276.35

Biogen Inc. (NASDAQ:BIIB) has been assigned an average recommendation of “Moderate Buy” from the twenty-five research firms that are currently covering the company, MarketBeat reports. Eight equities research analysts have rated the stock with a hold recommendation and seventeen have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $276.35.

A number of brokerages have recently commented on BIIB. Truist Financial reissued a “buy” rating and issued a $302.00 target price (down previously from $340.00) on shares of Biogen in a research note on Monday, August 5th. Wedbush cut their target price on shares of Biogen from $215.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, August 2nd. HSBC raised their target price on shares of Biogen from $339.00 to $342.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. Robert W. Baird cut their target price on shares of Biogen from $316.00 to $294.00 and set an “outperform” rating on the stock in a research note on Monday, July 29th. Finally, Royal Bank of Canada raised their target price on shares of Biogen from $282.00 to $292.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd.

Institutional Investors Weigh In On Biogen

A number of institutional investors have recently modified their holdings of the stock. Livelsberger Financial Advisory bought a new stake in shares of Biogen during the 4th quarter valued at about $26,000. Plato Investment Management Ltd grew its position in shares of Biogen by 82.8% during the 1st quarter. Plato Investment Management Ltd now owns 117 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 53 shares during the last quarter. Hexagon Capital Partners LLC grew its position in shares of Biogen by 76.1% during the 4th quarter. Hexagon Capital Partners LLC now owns 118 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 51 shares during the last quarter. Rise Advisors LLC bought a new stake in shares of Biogen during the 1st quarter valued at about $27,000. Finally, Itau Unibanco Holding S.A. bought a new stake in shares of Biogen during the 2nd quarter valued at about $33,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Stock Down 0.0 %

Shares of BIIB opened at $204.76 on Monday. The firm has a market cap of $29.81 billion, a PE ratio of 25.56, a price-to-earnings-growth ratio of 2.09 and a beta of -0.04. The company’s fifty day moving average is $215.73 and its two-hundred day moving average is $217.22. Biogen has a fifty-two week low of $189.44 and a fifty-two week high of $270.50. The company has a quick ratio of 1.32, a current ratio of 2.29 and a debt-to-equity ratio of 0.40.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $5.28 earnings per share for the quarter, beating analysts’ consensus estimates of $4.00 by $1.28. Biogen had a net margin of 11.98% and a return on equity of 15.71%. The company had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.39 billion. During the same quarter last year, the business earned $4.02 EPS. Biogen’s revenue for the quarter was up .4% on a year-over-year basis. Analysts forecast that Biogen will post 15.87 earnings per share for the current year.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.